Facet Biosystems, a biotechnology firm pioneering the event of bioprinted tissue therapeutics to rework how we deal with illness, is happy to announce the appointment of three new members to its Board of Administrators: Dr. Nancy Krieger, Dr. Don Haut, and Dr. Devyn Smith.
I’m excited to increase a heat welcome to Nancy, Don, and Devyn as they be part of Facet’s Board of Administrators. Every of them brings substantial expertise in regenerative medication and we’re thrilled to have them be part of our mission as we transfer in the direction of the subsequent stage of progress.”
Tamer Mohamed, Chief Government Officer, Facet Biosystems
About Facet’s new board members
Dr. Nancy Krieger is the Chief Medical Officer of Talaris Therapeutics, a just lately public late-clinical stage cell remedy biotech. She has over 18 years of worldwide expertise within the biopharmaceutical trade, together with management positions at Bristol Myers Squibb and Novartis in areas spanning stable organ and stem cell transplantation, immunology, uncommon problems, and continual kidney and liver ailments. Earlier than becoming a member of trade, Dr. Krieger had an energetic observe in liver transplantation in addition to a primary science laboratory. She accomplished her transplant fellowship on the College of Wisconsin and common surgical residency at Stanford College, together with a postdoctoral fellowship in Stanford’s immunology division. Dr. Krieger earned her MD at Columbia College School of Physicians and Surgeons.
I’m thrilled to be becoming a member of the Board of Facet Biosystems. As a transplant surgeon I’m passionate in regards to the large potential of Facet’s 3D bioprinting know-how for regenerative mobile therapies, with the last word chance of changing organ transplants with out the necessity for life-long immunosuppression.”
Dr. Nancy Krieger
Dr. Don Haut is at present the CEO of Carmine Therapeutics, a discovery-stage, non-viral gene remedy firm with operations in Boston and Singapore. All through his profession, Dr. Haut has accomplished transactions exceeding $8 billion. As Chief Enterprise Officer of AskBio, he led the agency’s enterprise improvement actions and spearheaded AskBio’s $4 billion acquisition by Bayer AG. Initially skilled as a molecular biologist earlier than becoming a member of McKinsey, Dr. Haut has since held senior enterprise roles at 3M Firm, Smith & Nephew, The Medicines Firm, Promedior, Histogenics, Sherlock Bio, and AskBio. He earned his PhD in Molecular Biology from the Medical College on the College of Missouri-Columbia, and an MBA from Washington College’s Olin College of Enterprise.
Once I first realized about what Facet Biosystems was doing, my first thought was ‘Wow!’. My second thought was ‘it will be nice to work with these of us – they’re actually onto one thing.’ So, I’m delighted to be becoming a member of Facet – the staff, the know-how, and the mission are all excellent.”
Dr. Don Haut
Dr. Devyn Smith joined Arbor Biotechnologies as CEO in 2021 after concluding his function as COO of Sigilon Therapeutics. Previous to Sigilon, Dr. Smith labored in quite a lot of roles at Pfizer Inc., together with COO of the UK-based Neusentis Unit centered on discovering and creating cell therapies. He obtained his PhD in Genetics from Harvard Medical College. He’s an inventor on a number of patents and has printed in main scientific journals all through his profession. Dr. Smith is a board member and officer for the Alliance for Regenerative Medication, the main worldwide advocacy group devoted to realizing the promise of regenerative medicines and superior therapies.
I’m excited to affix the board of Facet Biosystems. I sit up for partnering with Tamer and the gifted staff at Facet to construct a profitable firm that delivers novel mobile therapies to sufferers with excessive unmet wants.”
Dr. Devyn Smith
For full checklist of board members, go to: www.aspectbiosystems.com/about.